Literature DB >> 1309850

Antibodies to recombinant-derived glycoprotein B after natural human cytomegalovirus infection correlate with neutralizing activity.

G S Marshall1, G P Rabalais, G G Stout, S L Waldeyer.   

Abstract

Glycoprotein B (gB) of human cytomegalovirus (HCMV) was partially purified by lentil-lectin column chromatography from cells infected with an adenovirus-gB recombinant. This antigen, which contained specifically reactive proteins of approximately 130 and 55 kDa, was used to investigate gB antibody levels after natural HCMV infection in 48 individuals. All sera had IgG antibody to gB as detected by radioimmunoprecipitation (RIP) assays. Quantitative RIP showed a strong correlation between gB antibody and neutralizing activity (r = .74, P less than .001) but a weak correlation between gB antibody and total HCMV-specific IgG (r = .36, P less than .02). When gB antibody was specifically absorbed from 20 serum specimens, neutralizing antibody titer was reduced a median of 48% (range, 0-98%). These data confirmed that antibodies to gB are a large component of the neutralizing antibody response to HCMV and support a role for this protein in the development of subunit vaccines.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1309850     DOI: 10.1093/infdis/165.2.381

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  56 in total

1.  Distinct glycoprotein O complexes arise in a post-Golgi compartment of cytomegalovirus-infected cells.

Authors:  Regan N Theiler; Teresa Compton
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

2.  Complex formation by human cytomegalovirus glycoproteins M (gpUL100) and N (gpUL73).

Authors:  M Mach; B Kropff; P Dal Monte; W Britt
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  A trimeric capable gB CMV vaccine provides limited protection against a highly cell associated and epithelial tropic strain of cytomegalovirus in guinea pigs.

Authors:  K Yeon Choi; Nadia S El-Hamdi; Alistair McGregor
Journal:  J Gen Virol       Date:  2021-03-17       Impact factor: 3.891

4.  Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin.

Authors:  Ashley E Fouts; Pamela Chan; Jean-Philippe Stephan; Richard Vandlen; Becket Feierbach
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

Review 5.  Cytomegalovirus vaccines.

Authors:  Michael A McVoy
Journal:  Clin Infect Dis       Date:  2013-12       Impact factor: 9.079

6.  Humoral Immune Correlates for Prevention of Postnatal Cytomegalovirus Acquisition.

Authors:  Frances M Saccoccio; Jennifer A Jenks; Hannah L Itell; Shuk Hang Li; Madison Berry; Justin Pollara; Corey Casper; Soren Gantt; Sallie R Permar
Journal:  J Infect Dis       Date:  2019-07-31       Impact factor: 5.226

7.  In Vitro Characterization of Human Cytomegalovirus-Targeting Therapeutic Monoclonal Antibodies LJP538 and LJP539.

Authors:  Hetalkumar D Patel; Pavel Nikitin; Thomas Gesner; James J Lin; David T Barkan; Claudio Ciferri; Andrea Carfi; Tahmineh Akbarnejad Yazdi; Peter Skewes-Cox; Brigitte Wiedmann; Nadine Jarousse; Weidong Zhong; Adam Feire; Christy M Hebner
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

8.  Postoligomerization folding of human cytomegalovirus glycoprotein B: identification of folding intermediates and importance of disulfide bonding.

Authors:  M A Billstrom; W J Britt
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

9.  Vaccine prevention of maternal cytomegalovirus infection.

Authors:  Robert F Pass; Changpin Zhang; Ashley Evans; Tina Simpson; William Andrews; Meei-Li Huang; Lawrence Corey; Janie Hill; Elizabeth Davis; Cynthia Flanigan; Gretchen Cloud
Journal:  N Engl J Med       Date:  2009-03-19       Impact factor: 91.245

10.  Anti-human cytomegalovirus activity of cytokines produced by CD4+ T-cell clones specifically activated by IE1 peptides in vitro.

Authors:  J L Davignon; P Castanié; J A Yorke; N Gautier; D Clément; C Davrinche
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.